Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, 2. típus - cukorbetegségben szedett gyógyszerek - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Եվրոպական Միություն - հունգարերեն - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antitrombotikus szerek - possia, acetilszalicilsav (asa) együtt adják jelzi a felnőtt betegek akut coronaria szindrómák (instabil angina, nem-st-emelés miokardiális infarktus [nstemi] vagy st-emelés aterotrombotikus események megelőzése miokardiális infarktus [stemi]); gyógyszeresen kezelt betegek és azok, akik kezelik a percutan coronaria intervenció (pci), vagy koszorúér by-pass oltása (cabg).